Bacterial load determination is the gold-standard pharmacodynamic endpoint for evaluating anti-mastitis therapies, vaccine candidates, and pathogenesis studies in mouse models of mastitis. By quantifying colony-forming units (CFU) in mammary gland homogenates, blood, and distant organs, accredited third-party laboratories provide objective, reproducible data on bacterial colonization, replication, and clearance. This article outlines the technical principles, sample types, testing items, methods, applications, and frequently asked questions related to bacterial load measurement in murine mastitis models.
Technical Overview
Mastitis, the inflammation of mammary gland tissue, is most commonly induced in mice by intramammary (intracisternal or intraductal) inoculation of pathogenic bacteria into the inguinal mammary glands. Representative pathogens include Staphylococcus aureus, Escherichia coli, Streptococcus uberis, and Streptococcus agalactiae, which mirror the major etiological agents of clinical and subclinical bovine and human mastitis.
Bacterial load determination measures the number of viable bacteria recovered from infected tissue, expressed as log10 CFU per gram of mammary gland (CFU/g) or per milliliter of fluid (CFU/mL). Because it directly reflects whether a test article inhibits bacterial growth, promotes bacterial clearance, or fails to affect the infection, CFU quantification is regarded as the primary efficacy endpoint in preclinical anti-mastitis research.
Testing is typically performed in biosafety level 2 (BSL-2) facilities under institutional animal care and use committee (IACUC) approval, with study design, randomization, blinding, and reporting aligned with the ARRIVE 2.0 guidelines and, where required, the principles of OECD Good Laboratory Practice (GLP). Enumeration procedures follow internationally recognized microbiological standards, including ISO 7218, ISO 6887-1, ISO 4833-1, and applicable national food and clinical microbiology standards (GB 4789.2).
Testing Samples
Mammary Gland Tissue Homogenates (Primary Matrix)
The infected inguinal gland (typically the fourth pair, L4/R4) is dissected aseptically at defined time points post-infection, trimmed of fat and connective tissue, weighed, and homogenized in a known volume of sterile phosphate-buffered saline (PBS). This is the core sample for determining tissue bacterial burden, reported as log10 CFU/g.
Mammary Gland Lavage Fluid and Milk
In lactating dam models, milk samples or gland lavage fluid can be collected to quantify the bacterial content in the ductal compartment. Results are reported as log10 CFU/mL and provide information on shedding and intraductal persistence.
Blood
Systemic blood samples obtained by cardiac puncture or retro-orbital sampling are cultured quantitatively to assess bacteremia and systemic spread, which is particularly relevant in E. coli models that can progress to sepsis.
Distant Organs
Liver, spleen, kidney, and lung homogenates may be plated to evaluate hematogenous dissemination of the pathogen beyond the mammary gland, an important safety-relevant readout when evaluating anti-inflammatory or immunomodulatory therapies.
Testing Items
The standard testing panel for bacterial load determination in the murine mastitis model includes the following items:
- Total viable aerobic bacterial count in mammary gland tissue (log10 CFU/g)
- Species-specific bacterial enumeration on selective or differential media (for example, Baird-Parker agar for S. aureus, MacConkey agar for E. coli, and Edwards or blood agar for streptococci)
- Bacterial burden in blood (log10 CFU/mL) and distant organs (log10 CFU/g)
- Inoculum verification (back-titration of the challenge dose administered to each cohort)
- Limit of detection (LOD) determination and reporting of non-detect samples using predefined substitution rules
- Optional complementary endpoints: histopathological scoring of mammary inflammation, myeloperoxidase (MPO) activity, inflammatory cytokine profiling (TNF-α, IL-1β, IL-6), and qPCR-based bacterial DNA quantification targeting species-specific genes or 16S rRNA
Testing Methods
Model Establishment and Infection
Overnight or log-phase bacterial cultures are washed, resuspended in sterile PBS, and adjusted to the target challenge dose (commonly 102 to 105 CFU per gland depending on the pathogen and study design). Under anesthesia, a small volume (typically 10–50 µL) is infused through the teat canal into the mammary gland cistern. The actual administered dose is confirmed retrospectively by plate counting of the inoculum, ensuring that challenge levels remain within the predefined specification.
Sample Collection and Processing
At predetermined time points (commonly 12, 24, 48, and 72 hours post-infection), animals are humanely euthanized according to AVMA guidelines. Mammary glands are excised under aseptic conditions, blotted, weighed, and homogenized in chilled sterile PBS (or PBS containing a low concentration of nonionic surfactant to release intracellular bacteria). Blood and organs are processed in parallel when dissemination endpoints are included.
Serial Dilution and Plate Counting
Hundreds of microliters of homogenate are subjected to 10-fold serial dilutions in sterile diluent prepared in accordance with ISO 6887-1. Aliquots of each dilution are plated in duplicate or triplicate onto nonselective agar (tryptic soy agar or 5% sheep blood agar) and pathogen-appropriate selective media using the spread-plate or drop-plate (Miles-Misra) technique. Plates are incubated aerobically at 37°C for 18–24 hours (or up to 48 hours for slow-growing strains), and colonies within the valid counting range (typically 30–300 CFU for standard plates, or 3–30 CFU for drop plates) are counted. CFU/g is calculated as: colony count × dilution factor × homogenate volume ÷ (plated aliquot volume × tissue mass).
Data Analysis and Reporting
Raw CFU values are log10-transformed before statistical analysis because bacterial counts are approximately log-normally distributed. Samples below the LOD are handled using a predefined rule (for example, assigning half of the LOD value). Group comparisons are performed using one-way or two-way ANOVA with appropriate post-hoc tests, or nonparametric equivalents such as Kruskal-Wallis tests, with sample sizes justified by power analysis. Culture media performance and incubation conditions are quality-controlled in line with ISO 11133, and all procedures are executed under ISO 7218 general microbiology requirements to ensure traceable, defensible results.
Applications
Bacterial load determination in mouse mastitis models supports a wide range of preclinical research and development activities:
- In vivo efficacy evaluation of new antibiotics, including dose-response and PK/PD relationship studies for anti-mastitis drug candidates
- Assessment of non-antibiotic anti-infective strategies, such as antimicrobial peptides, bacteriophage therapy, botanical extracts, nanoparticles, and monoclonal antibodies
- Immunogenicity and protective efficacy testing of mastitis vaccine candidates and passive immunization preparations
- Evaluation of probiotics (for example, lactobacilli) and natural compounds for the prevention or mitigation of intramammary infection
- Adjunct therapy studies combining antimicrobial agents with anti-inflammatory or immunomodulatory treatments
- Pathogenesis and virulence research, including comparisons of wild-type strains with gene-knockout mutants or biofilm-forming clinical isolates
- Translational dairy science research that bridges murine proof-of-concept data with subsequent bovine mastitis trials
FAQ
Which mouse strains are commonly used?
C57BL/6, BALB/c, and ICR (CD-1) mice are the most frequently used strains. Lactating dams (typically 8–14 days postpartum) are preferred for models that mimic puerperal or lactation-associated mastitis, while nulliparous females may be used for simplified screening models.
Why are results reported as log10 CFU/g rather than raw CFU values?
Bacterial populations expand logarithmically and their counts are log-normally distributed. Log transformation normalizes the variance across groups, enables valid parametric statistical testing, and presents treatment effects (often reductions of several orders of magnitude) on an interpretable scale.
What is the limit of detection of the assay?
The practical LOD depends on the homogenate volume, dilution scheme, and plated aliquot volume, and is commonly in the range of 1.7–2.0 log10 CFU/g of tissue. The LOD is defined in the study protocol and applied consistently when reporting sterile or near-sterile glands, which may indicate complete bacterial clearance.
Can qPCR replace culture-based CFU counting?
No. qPCR quantifies bacterial DNA from both live and dead organisms and cannot confirm viability, whereas culture-based enumeration measures only viable, culturable bacteria. The two methods are complementary: CFU counting remains the primary efficacy endpoint, while qPCR offers faster turnaround and higher analytical sensitivity for supporting or confirmatory analyses.
How many animals and time points are required?
A typical design includes 6–10 mice per group per time point, justified by statistical power analysis based on expected effect size and variability. Common sampling windows are 24 and 48 hours post-infection, with 72-hour or later endpoints added to evaluate bacterial persistence and clearance kinetics.
What is the typical turnaround time?
Excluding protocol-specific customization, the animal phase generally requires 3–7 days depending on infection duration, followed by 24–48 hours of incubation for CFU enumeration and additional time for data analysis. A complete GLP-compliant or non-GLP study report, including methodology, individual and group data, and statistical evaluation, is typically delivered within 2–4 weeks.
How is animal welfare ensured?
All procedures are reviewed and approved by the IACUC or equivalent ethics committee. Studies incorporate humane endpoints, close clinical monitoring, appropriate anesthesia and analgesia, and the 3Rs principles (replacement, reduction, and refinement) in full accordance with applicable national regulations and international animal care standards.